While treatment with trastuzumab is the standard of care for HER2-positive locally advanced or metastatic breast cancer and gastric cancer, data on long-term use of the biologic are lacking, and cardiac risk related to trastuzumab has posed concerns.
While treatment with trastuzumab is the standard of care for HER2-positive locally advanced or metastatic breast cancer and gastric cancer, data on long-term use of the biologic are lacking, and cardiac risk related to trastuzumab has posed concerns. In a new study in BMC Cancer, researchers reported findings from the Rollover Protocol Study that collected safety data on long-term trastuzumab therapy (5 or more years in patients with HER2-positive breast cancer and 3 or more years in patients with gastric cancer).
In total, 19 patients with breast cancer and 6 patients with gastric cancer who had stable disease received long-term trastuzumab therapy during the study. The patients previously treated with trastuzumab continued to receive the drug at a loading dose of 4 mg/kg followed by weekly 2-mg/kg maintenance doses beginning 3 weeks after the loading dose. Therapy continued until progression, lack of treatment benefit, toxicity, patient decision, or patient death.
All patients discontinued treatment by the study’s end, due to adverse events (AEs), insufficient response, a switch to commercially available trastuzumab or subcutaneous trastuzumab outside the study context, patient decision, investigator decision, or sponsor request. The median duration of treatment in the breast cancer group was 8 years and 7 months (range, 5 years and 4 months to 13 years and 11 months). In the gastric cancer group, the median duration of treatment was 5 years and 2 months (range, 3 years and 4 months to 7 years and 4 months).
While the risk of cardiac AEs is a concern with trastuzumab treatment, in the 20 patients who had left ventricular ejection fraction (LVEF) measurements available, the cardiac status of these patients remained stable over time; no marked changes in LVEF were observed.
Of the total group, 7 patients (28.0%) reported serious AEs (SAEs), none of which were considered related to trastuzumab treatment. Reported SAEs were pain, septic arthritis, erysipelas, lung cancer, fibula fracture, urinary tract infection, and a broken leg. There were no reports of cardiac SAEs, and there were no deaths during the study period.
The authors conclude that, in patients who received long-term treatment for their HER2-positive disease, trastuzumab had an acceptable safety profile and was well tolerated. “Stable LVEF outcomes and the absence of cardiac SAEs suggest that long-term [trastuzumab] therapy is feasible and without any additional cardiac safety risk, particularly with continued patient care and monitoring according to standard practice,” write the authors.
Reference
Müller V, Clemens M, Jassem J, et al. Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. BMC Cancer. 2018;18:295. doi: 10.1186/s12885-018-4183-2.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Top 5 Most-Read Oncology Articles of 2024
December 24th 2024The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer Ingelheim layoffs, the safety of rituximab biosimilar CT-P10, and more.